Advicenne Announces Its Participation in Several Scientific Conferences and the Presentation of Updated Clinical Results About ADV7103

PARIS--(BUSINESS WIRE)--Regulatory News:

Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces the presentation of the latest results from the ARENA-1 clinical development program at scientific conferences.

Didier Laurens, Chief Executive Officer of Advicenne, comments: "We are delighted to present updated results of the ARENA-1 study to the European nephrology community. This 72-month follow-up study enables doctors and caregivers to better understand challenges of long-term treatment of distal renal tubular acidosis (dRTA), as well as benefits of ADV7103. These results are major and are thus strengthening our ongoing discussions with the FDA in view of optimizing its clinical and commercial development across the USA".

Following an initial presentation of the results of ADV7103 treatment of patients with distal Renal Tubular Acidosis (dRTA) in June 2023 at the annual congress of the European Renal Association (ERA), the updated results will be presented both in oral and poster sessions during the following conferences:

• European Society of Pediatric Nephrology (ESPN), September 28 to October 1, 2023 - Vilnius (Lithuania)

Title: Long-term clinical outcomes in patients with distal renal tubular acidosis after 6 years treatment with Sibnayal® (ADV7103)
Authors: Dr. Aurélia Bertholet et al.
Session: Symposium 5 – Diagnostics (Oral presentation, September 30)

Title: Sibnayal® (ADV7103), an innovative product with sustained release, effective in the treatment of dRTA patients
Authors: Dr. Aurélia Bertholet et al.
Session: Innovation & Industry Best Pitches (September 30)

• Société Francophone de Néphrologie, Dialyse et Transplantation (SFNDT), October 3-6, 2023 – Liège (Belgium)

Title: Long-term clinical outcomes in patients with distal renal tubular acidosis receiving prolonged release potassium citrate and potassium carbonate: data at 6 years
Authors: Dr. Aurélia Bertholet et al.
Session: Poster PO-NO4 (October 3 & 4)

About Advicenne
Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: https://advicenne.com/.

Disclaimer
This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2022 Universal Registration Document filed with the French financial market authority on April 28, 2023 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.